Physician profile
Maria A Herrera
NPI 1134170897
$8,322.42
in general payments reported to CMS, 2019-2025
54 companies · $2,533 in 2025
The $2,533 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $268 · 2021: $1,410 · 2022: $890 · 2023: $883 · 2024: $2,213 · 2025: $2,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,522 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,522.27 |
| Education | $105.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,087.62 | 2021-2025 | |
| Pfizer INC. | $499.22 | 2021-2025 | |
| Biogen, INC. | $469.20 | 2020-2025 | Leqembi, Tysabri, Vumerity |
| Catalyst Pharmaceuticals, INC. | $415.17 | 2023-2025 | Fycompa |
| Amgen INC. | $360.96 | 2021-2025 | Uplizna |
| Lilly USA, LLC | $342.45 | 2020-2025 | Amyvid, Kisunla, Emgality |
| Lundbeck LLC | $309.88 | 2024-2025 | Vyepti, Rexulti |
| Ucb, INC. | $309.79 | 2021-2025 | Rystiggo, Briviact |
| Alexion Pharmaceuticals, INC. | $302.64 | 2019-2025 | Ultomiris |
| Biohaven Pharmaceutical Holding Company LTD. | $296.58 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $296.38 | 2023-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $275.05 | 2019-2025 | Austedo Xr, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $272.37 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $210.43 | 2021 | |
| Upsher-Smith Laboratories LLC | $188.48 | 2020-2023 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $186.18 | 2021-2025 | Hyqvia, Gammagard |
| Janssen Biotech, INC. | $175.83 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $171.85 | 2025 | Wainua |
| Novartis Pharmaceuticals Corporation | $171.65 | 2019-2025 | |
| Argenx US, INC. | $160.89 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $153.22 | 2022-2025 | |
| Scilex Pharmaceuticals INC. | $121.64 | 2023-2024 | Ztlido |
| Novo Nordisk INC | $120.65 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $100.58 | 2024-2025 | Acthar |
| Octapharma USA, INC. | $91.60 | 2022-2024 | Panzyga |
| Adamas Pharmaceuticals, INC. | $79.05 | 2020-2021 | |
| Axsome Therapeutics, INC. | $77.46 | 2025 | Symbravo |
| Emd Serono, INC. | $77.14 | 2024-2025 | |
| Allergan, INC. | $76.07 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $73.25 | 2024-2025 | Xeomin, Inbrija |
| Amneal Pharmaceuticals LLC | $67.88 | 2020-2024 | Rytary, Ongentys |
| Abbott Laboratories | $67.53 | 2023-2025 | Infinity, Eterna |
| Acorda Therapeutics, INC | $59.51 | 2021-2023 | Inbrija |
| W. L. Gore & Associates, INC. | $55.18 | 2023 | Gore Tag Thoracic Branch Endoprosthesis |
| Neurocrine Biosciences, INC. | $49.06 | 2022 | |
| Genentech USA, INC. | $43.47 | 2022-2025 | Ocrevus Zunovo |
| Life Molecular Imaging LTD | $43.02 | 2025 | Neuraceq |
| Vanda Pharmaceuticals INC. | $42.06 | 2025 | Ponvory |
| Tg Therapeutics, INC. | $41.39 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $41.26 | 2021-2024 | Nuplazid |
| Celgene Corporation | $37.05 | 2023 | Zeposia |
| Grifols USA, LLC | $35.18 | 2020-2022 | |
| Akcea Therapeutics, INC. | $30.81 | 2021 | |
| C2n Diagnostics, LLC | $29.99 | 2025 | Precivityad2 |
| Livanova USA, INC. | $28.66 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Boston Scientific Corporation | $28.59 | 2023 | |
| Aucta Pharmaceuticals, INC. | $27.61 | 2025 | Motpoly Xr |
| Tanabe Pharma America, INC. | $24.26 | 2025 | Radicava |
| Neurelis, INC. | $19.78 | 2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $18.66 | 2020 | |
| Insightec,INC | $18.43 | 2023 | Exablate |
| Genzyme Corporation | $14.81 | 2019 | |
| Grt US Holding, INC. | $12.58 | 2022 | |
| Csl Behring | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.